Company intelligence / Profile preview

MEI HENG

Shantou, Guangdong Province, Chinamath.ntnu.edu.tw ↗

Ownership: Private
Development stage: Other

Overview

MEI HENG, affiliated with Wuhan Union Hospital, China, is responsible for an early-stage clinical study evaluating antibody-based therapies in Hodgkin's Granuloma. No published results yet; status indicates ongoing recruitment or recent initiation.

Therapeutic areas: Oncology
Modalities: Antibody
Industry: Biotech

Partnerships

SupermAb [BeiJing] Biotech Co., Ltd.

Beyond the preview

Go deeper on MEI HENG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEI HENG.

Explore the full profile